» Articles » PMID: 27292311

Guillain-Barré Syndrome: Causes, Immunopathogenic Mechanisms and Treatment

Overview
Date 2016 Jun 14
PMID 27292311
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

Guillain-Barré syndrome is a rare disease representing the most frequent cause of acute flaccid symmetrical weakness of the limbs and areflexia usually reaching its peak within a month. The etiology and pathogenesis remain largely enigmatic and the syndrome results in death or severe disability in 9-17% of cases despite immunotherapy. Areas covered: In terms of etiology, Guillain-Barré syndrome is linked to Campylobacter infection but less than 0.1% of infections result in the syndrome. In terms of pathogenesis, activated macrophages and T cells and serum antibodies against gangliosides are observed but their significance is unclear. Expert commentary: Guillain-Barré syndrome is a heterogeneous condition with numerous subtypes and recent data point towards the role of ganglioside epitopes by immunohistochemical methods. Ultimately, the syndrome results from a permissive genetic background on which environmental factors, including infections, vaccination and the influence of aging, lead to disease.

Citing Articles

Causal relationship between immune cells and Guillain-Barré syndrome: a Mendelian randomization study.

Liu H, Shao S, Chen B, Yang S, Zhang X Front Neurol. 2024; 15:1446472.

PMID: 39600430 PMC: 11588641. DOI: 10.3389/fneur.2024.1446472.


Lactobacillus rhamnosus ameliorates experimental autoimmune neuritis via modulation of gut microbiota and metabolites.

Shi P, Li Y, Yang H, Li Q, Li Q, Ye M Heliyon. 2024; 10(21):e39126.

PMID: 39524841 PMC: 11550083. DOI: 10.1016/j.heliyon.2024.e39126.


Guillain-Barré Syndrome and Encephalitis Following a Cytomegalovirus Infection in an Immunocompetent Adult: A Case Report.

Coelho D, Melo Mendes I, Mamani R, Oliveira da Luz R, Martins de Oliveira A, Pimentel C Am J Case Rep. 2024; 25:e944337.

PMID: 39021063 PMC: 11304682. DOI: 10.12659/AJCR.944337.


The Impact of COVID-19 on the Guillain-Barré Syndrome Incidence.

Kopanko M, Zabludowska M, Zajkowska M, Gudowska-Sawczuk M, Mucha M, Mroczko B Biomedicines. 2024; 12(6).

PMID: 38927455 PMC: 11201746. DOI: 10.3390/biomedicines12061248.


Intracranial Hemorrhage in a Patient With Guillain-Barré Syndrome: A Potential Complication, a Coincidental Finding or a Treatment-Related Complication.

Kanna S, Mixides G, Michaelides C Cureus. 2024; 16(3):e57174.

PMID: 38681422 PMC: 11056031. DOI: 10.7759/cureus.57174.